We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Empagliflozin

News List

Boehringer, Lilly Get Complete Response Letter for Empagliflozin contractpharma
March 24, 2020
FDA is unable to approve sNDA for Empagliflozin in type 1 diabetes.
FDA Grants Fast Track Designation to Empagliflozin for Chronic Heart Failure americanpharmaceuticalreview
June 28, 2019
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure ...
Oxford Uni, Boehringer, Lilly link to test Jardiance in kidney disease pharmatimes
July 16, 2018
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
First dedicated outcome trials of empagliflozin in chronic heart failure initiated lilly
March 20, 2017
EMPEROR HF clinical trial program will evaluate the efficacy and safety of empagliflozin in patients with chronic heart failure, including those with and without type 2 diabetes

Previous page 1 2 Next page